Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2017

Study Completion Date

July 31, 2017

Conditions
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Interventions
DRUG

Metformin

"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT01579812 - Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients | Biotech Hunter | Biotech Hunter